Drug Trial Radar · NCT06715683
A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Dec 12, 2024
Primary completion
Mar 16, 2025
Study completion Mar 16, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a trial to evaluate the comparative bioavailability of BMS-986278 to-be-marketed formulation compared to the phase 3 clinical trial formulation in healthy participants.
Conditions
- Healthy Volunteers
Interventions
BMS-986278 Batched method, Dose ADrug
Specified dose on specified days
BMS-986278 Batched method, Dose BDrug
Specified dose on specified days
BMS-986278 Continuous methodDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax)Time frame: Up to Day 24
- Area Under the Concentration-time From Time Zero to Time Last Qualifiable Concentration (AUC(0-T))Time frame: Up to Day 24
- Area Under the Concentration-time From Time Zero Extrapolated to Infinite Time (AUC(INF))Time frame: Up to Day 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anaheim Clinical Trials (ACT)
Anaheim, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.